List view / Grid view
New agreement reserves million doses of GSK’s pandemic influenza vaccine…
New agreement reserves million doses of GSK’s pandemic influenza vaccine Adjupanrix to support Europe’s pandemic preparedness.
Under a new agreement, GlaxoSmithKline will provide the fill and…
Under a new agreement, GlaxoSmithKline will provide the fill and finish manufacturing capacity for 60 million doses of Novavax’ COVID-19 vaccine for use in the UK.
Sanofi and GSK have agreed to support the COVID-19 vaccine…
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
The trial will evaluate the safety, tolerability and immunogenicity of…
The trial will evaluate the safety, tolerability and immunogenicity of the duo’s COVID-19 recombinant protein-based vaccine candidate in 440 healthy US participants.
Sanofi and GSK have reached an agreement with the UK…
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
